Buserelin vs Leuprolide — Peptide Comparison

Buserelin vs Leuprolide — Peptide Comparison Buserelin vs Leuprolide — compare dosing, benefits, safety profiles, side effects, and how they stack. See which peptide is right for you. At a Glance Dose Range Buserelin 200 mcg–1,500 mcg mcg Leuprolide 3.75 mg–45 mg monthly or 3-month injections (depending on formulation) Frequency Once daily Administration Subcutaneous injection Subcutaneous injection (daily) Cycle Length Ongoing/indefinite Onset Speed Moderate (1-2 weeks) Evidence Level Strong human trials (Phase 3 or FDA approved) Efficacy Hormone Suppression Cancer Management Fertility Support Endometriosis & Fibroid Relief Hormone Control Technical Data Molecular Formula C60H86N16O13 Molecular Weight 1239.4 g/mol Half-Life 2-4 hours (subcutaneous), 30-60 minutes (intranasal); longer for depot formulation (28-40 days) Bioavailability ~1% (oral); ~10-15% (intranasal); ~95% (subcutaneous) CAS Number 57773-65-6 C59H84N16O12 1209.4 g/mol Approximately 2-6 hours (varies by route of administration) ~95% (subcutaneous injection) 74381-53-6 Protocols starting 500 mcg Every 8 hours (3 times daily) First 7 days The product label starts prostate cancer treatment with 500 mcg under the skin every 8 hours for the first week [5]. standard 200 mcg Ongoing maintenance After the first week, the label switches to 200 mcg once daily under the skin for ongoing treatment [5]. 400 mcg (2 sprays per nostril) 3 times daily (1,200 mcg/day) The nasal spray option delivers 400 mcg three times a day as maintenance, an alternative to daily injections [5]. 6.3 mg Once every 2 months Long-term A long-acting implant placed under the skin slowly releases buserelin over about 2 months, so no daily dosing is needed [5]. advanced 9.45 mg Once every 3 months A larger implant lasts about 3 months between placements [5]. 1 mg Ongoing The original daily form is a 1 mg shot under the skin each day for advanced prostate cancer. It works but needs a shot every day, so most people now use the longer-acting depot instead [4]. 7.5 mg Every month The 1-month depot is a single 7.5 mg shot into the muscle every 4 weeks. One injection replaces a month of daily shots [5]. 22.5 mg Every 3 months The 3-month depot is a 22.5 mg muscle injection given once every 3 months, so fewer office visits [5]. 30-45 mg Every 4-6 months The longest-acting depots: 30 mg every 4 months, or 45 mg every 6 months. These need only 2-3 injections per year [5]. Applications Managing advanced prostate cancer Buserelin is particularly well-suited for individuals focused on managing advanced prostate cancer. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Treating endometriosis and reducing associated pain Buserelin is particularly well-suited for individuals focused on treating endometriosis and reducing associated pain. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Optimizing ovarian response during fertility treatments Buserelin is particularly well-suited for individuals focused on optimizing ovarian response during fertility treatments. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Managing advanced or metastatic prostate cancer Leuprolide is particularly well-suited for individuals focused on managing advanced or metastatic prostate cancer. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Controlling severe endometriosis pain Leuprolide is particularly well-suited for individuals focused on controlling severe endometriosis pain. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Treating symptomatic uterine fibroids Leuprolide is particularly well-suited for individuals focused on treating symptomatic uterine fibroids. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Delaying early puberty in children Leuprolide is particularly well-suited for individuals focused on delaying early puberty in children. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Safety Profile Common Hot flashes (very common in men) Decreased libido and erectile dysfunction Injection site pain or swelling Nausea Fatigue Mood changes or depression Joint or muscle pain Headaches Dizziness Thinning hair Decreased bone density (osteoporosis with long-term use) QT prolongation (rare but serious cardiac effect) Tumor flare (temporary worsening of cancer symptoms in first weeks) Severe allergic reactions Spinal cord compression risk in men with metastatic disease Serious Severe allergic reaction Research Status FDA Status FDA approved for other use Safety Overview Buserelin is an FDA-approved GnRH agonist with safety data from Phase 3 trials and decades of clinical use, but carries well-documented risks from intentional testosterone/estrogen suppression. The initial testosterone flare (first 2-3 weeks) can worsen prostate cancer symptoms and cause tumor flare pain in 10-20% of patients. Long-term use causes bone density loss of 2-3% annually, with vertebral fractures in 10-20% of long-term users. Cardiovascular risks include increased MI and stroke in men over 65. Hot flashes affect 40-80%, erectile dysfunction is nearly universal, and liver enzyme elevations occur in 5%. Nasal spray formulation causes local irritation in 20-30% of users. Contraindications xPregnancy or breastfeeding xHypersensitivity to GnRH agonists xCertain bone diseases when long-term use is planned FDA approved for this use Leuprolide (Lupron) is an FDA-approved GnRH agonist with 35+ years of clinical safety data involving millions of patients in oncology and endocrinology. The critical safety issue is the initial 5-7 day flare effect—temporary surge in FSH/LH causing symptom worsening before hormone suppression begins—particularly dangerous for prostate cancer patients (flare can cause urinary obstruction or spinal cord compression). Bone density loss is a dose-dependent long-term risk in both men and women requiring monitoring. Injection site reactions, hot flushes, and initial hypogonadal symptoms are expected and typically transient. xPregnancy or breastfeeding (teratogenic) xUndiagnosed vaginal bleeding xActive bone metastases with spinal cord compression (increased fracture risk) xAllergy to GnRH agonists or components xSevere cardiovascular disease with QT prolongation risk Decision Guide Choose Buserelin if... Managing advanced prostate cancer Treating endometriosis and reducing associated pain Optimizing ovarian response during fertility treatments Choose Leuprolide if... Managing advanced or metastatic prostate cancer Controlling severe endometriosis pain Treating symptomatic uterine fibroids Delaying early puberty in children